Dual-association of gnotobiotic IL-10-/- mice with 2 nonpathogenic commensal bacteria induces aggressive pancolitis

Inflammatory Bowel Diseases

Volumn 13, Issue 12, 2007, Pages 1457-1466

  Kim, Sandra C ^a   Tonkonogy, Susan L ^b   Karrasch, Thomas ^a   Jobin, Christian ^a   Balfour Sartor, R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Commensal bacteria; Gnotobiotic IL 10 mice; Pancolitis

Indexed keywords

ACEBUTOLOL; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23P40; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM CULTURE; BACTEROIDES VULGATUS; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL STIMULATION; CONTROLLED STUDY; CULTURE MEDIUM; DILUTION; DUODENUM; ENTEROCOCCUS FAECALIS; ENTEROPATHY; ESCHERICHIA COLI; GNOTOBIOTICS; INFLAMMATION; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PANCOLITIS; PHENOTYPE; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; COLITIS; COLON; COLONY COUNT, MICROBIAL; DUODENITIS; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GERM-FREE LIFE; GRAM-POSITIVE BACTERIAL INFECTIONS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-23; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; UP-REGULATION;

EID: 38049004922     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20246     Document Type: Article

References (32)

1. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.
2. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998;66: 5224-5231.
3. Dieleman LA, Arends A, Tonkonogy SL, et al. Helicobacter hepaticus does not induce or potentiate colitis in interleukin-10 deficient mice. Infect Immun. 2000;68:5107-5113.
4. Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest. 1996;98:945-953.
5. Rath HC, Wilson KH, Sartor RB. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus and Escherichia coli. Infect Immun. 1999;67:2969-2974.
6. Sutton CL, Kim J, Yamane A, et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology. 2000;119: 23-31.
7. Kim SC, Tonkonogy SL, Albright CA, et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology. 2005;128:891-906.
8. Magness ST, Jijon H, Van Houten F, et al. In vivo pattern of lipopolysaccharide and anti-CD3-induced NF-kappa B activation using a novel gene-targeted enhanced GFP reporter gene mouse. J Immunol. 2004; 173:1561-1570.
9. Balish E, Warner T. Enterococcus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice. Am J Pathol. 2002;160:2253-2257.
10. Veltkamp C, Tonkonogy SL, de Jong YP, et al. Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg(epsilon26) mice. Gastroenterology. 2001;120: 900-913.
11. Onderdonk AB, Bronson R, Cisneros R. Comparison of Bacteroides vulgatus strains in the enhancement of experimental ulcerative colitis. Infect Immun. 1987;55:835-836.
12. Jobin C, Haskill S, Mayer L, et al. Evidence for altered regulation of I kappa B alpha degradation in human colonic epithelial cells. J Immunol. 1997;158:226-234.
13. Kim JS, Jobin C. The flavonoid luteolin prevents lipopolysaccharide- induced NF-kappaB signalling and gene expression by blocking IkappaB kinase activity in intestinal epithelial cells and bone-marrow derived dendritic cells. Immunology. 2005;115:375-387.
14. EGFP mice reveal the critical role of TLR/NFB signaling in commensal bacteria-induced colitis. J Immunol. 2007;178:6522-6532.
15. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116:1310-1316.
16. Sadlack B, Merz H, Schorle H, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 1993;75:253-261.
17. Schultz M, Tonkonogy SL, Sellon RK, et al. IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation. Am J Physiol 1999;276(6 Pt 1):G1461-G1472.
18. Waidmann M, Bechtold O, Frick JS, et al. Bacteroides vulgatus protects against Escherichia coli-induced colitis in gnotobiotic interleukin-2-deficient mice. Gastroenterology. 2003;125:162-177.
19. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390-407.
20. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol. 1995;102:448-455.
21. Duchmann R, May E, Heike M, et al. T cell specificity and cross reactivity towards Enterobacteria, Bacteroides, Bifidobacterium, and antigens from resident intestinal flora in humans. Gut. 1999;44:812-818.
22. Cartun RW, Van Kruiningen HJ, Pedersen, CA, et al. An immunocytochemical search for infectious agents in Crohn's disease. Mod Pathol. 1993;6:212-219.
23. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology. 1998;115:1405-1413.
24. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005;128:2020-2028
25. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44-54.
26. Swidsinski A, Weber J, Loening-Baucke V, et al. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol. 2005;43:3380-3389.
27. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004;126:414-424.
28. Papadakis KA, Yang H, Ippoliti A, et al. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis. 2007;13:524-530.
29. Hoentjen F, Harmsen HJ, Braat H, et al. Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin-10 gene deficient mice. Gut. 2003;52:1721-1727.
30. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut. 1991;32:1071-1075.
31. Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol. 1998;12:53-56.
32. Mow WS, Landers CJ, Steinhart AH, et al. High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study. Dig Dis Sci. 2004;49:1280-1286.